Spyre Therapeutics Inc. (NASDAQ:SYRE) has a beta value of 2.93 and has seen 1.13 million shares traded in the last trading session. The company, currently valued at $1.56B, closed the last trade at $30.66 per share which meant it gained $1.96 on the day or 6.83% during that session. The SYRE stock price is -56.46% off its 52-week high price of $47.97 and 72.5% above the 52-week low of $8.43. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.36 million shares traded. The 3-month trading volume is 480.08K shares.
The consensus among analysts is that Spyre Therapeutics Inc. (SYRE) is Buy stock at the moment, with a recommendation rating of 1.11. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.83.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Spyre Therapeutics Inc. (NASDAQ:SYRE) trade information
Sporting 6.83% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the SYRE stock price touched $30.66 or saw a rise of 0.13%. Year-to-date, Spyre Therapeutics Inc. shares have moved 42.47%, while the 5-day performance has seen it change 11.49%. Over the past 30 days, the shares of Spyre Therapeutics Inc. (NASDAQ:SYRE) have changed 4.43%. Short interest in the company has seen 8.64 million shares shorted with days to cover at 13.59.
Wall Street analysts have a consensus price target for the stock at $40, which means that the shares’ value could jump 23.35% from current levels. The projected low price target is $40.0 while the price target rests at a high of $40.0. In that case, then, we find that the current price level is -30.46% off the targeted high while a plunge would see the stock gain -30.46% from current levels.
Spyre Therapeutics Inc. (SYRE) estimates and forecasts
Figures show that Spyre Therapeutics Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -17.58% over the past 6 months, with this year growth rate of 87.73%, compared to 17.40% for the industry. Revenue growth from the last financial year stood is estimated to be 351.50%.
5 have an estimated revenue figure of 4M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 1.60% over the past 5 years.
SYRE Dividends
Spyre Therapeutics Inc. is expected to release its next earnings report in November this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Fidelity Growth Company Fund . As of Jun 30, 2024 , the former fund manager holds about 2.16% shares in the company for having 1.1 shares of worth $33.71 million while later fund manager owns 1.05 shares of worth $32.19 million as of Aug 31, 2024 , which makes it owner of about 2.06% of company’s outstanding stock.
